Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc by Lei Wang (6656)

“…The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”

Madrasin decreases transcription of protein-coding genes. by Michael Tellier (8284752)

Madrasin decreases transcription of protein-coding genes. by Michael Tellier (8284752)

Boxplot comparing Ct values for HD in flies and clothes. by Philippe Ndzomo (17706039)

S1 Data. Bibliometric analysis. S2 Data. Estrogen level analysis. S3 Data. MicroCT quantification. S4 Data. Markers of bone metabolism. by Yan She (8639796)

Measurements of viral RNAs by RNA-seq in non-immortalized and immortalized co-transformed cells grown <i>in vitro</i> and as tumors in the peritoneal cavities of NSG mice and of PE... by Mitchell Hayes (5334887)

Estimated detected and non-detected colorectal cancer rates and their clinical stages based on colorectal cancer screening in Minamisoma City in 2011. by Hiroaki Saito (24514)

Avoided recurrences and costs with adjuvant atezolizumab for patients with early non-small cell lung cancer in Europe by Alastair Greystoke (9562178)

“…<p>This study estimated avoided recurrences and treatment costs in patients with stage II-IIIA non-small cell lung cancer treated with adjuvant atezolizumab in five European countries over 10 years (2024–2034).…”

DataSheet1_Decreasing viscosity and increasing accessible load by replacing classical diluents with a hydrotrope in liquid–liquid extraction.docx by Asmae El Maangar (19690522)

Data and code from: Continental declines in North American small mammal populations by Alec Medd (20968740)

“…Contrary to our initial speculation, we found strong support for an overall decline in North American small mammal abundance, with an estimated annual decrease of 3.6%. …”

Skin marks is the S1 Fig title. by Mercedes Soto-González (20422078)

C-terminal tagging of NCAPH2 can either increase or decrease protein expression. by Gillian C. A. Taylor (3909568)

<b>FOXP3 influences recruitment and polarization of macrophages via regulating CCL5 in non-small cell lung cancer</b> by Zhihua Ye (20486717)

“…<p dir="ltr">Forkhead box P3<b> (</b>FOXP3) plays a key role in the malignant progression of non-small cell lung cancer (NSCLC). However, the regulatory effect of FOXP3 on the biological activity of macrophages in NSCLC has not yet been reported.…”

Image 4_Vitexicarpin suppresses colorectal and non-small cell lung cancer via selective inhibition of Anoctamin 1.jpeg by Yohan Seo (773204)

“…<p>Colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) remain among the most challenging malignancies to treat due to therapy complexity, adverse events, and dose-limiting toxicities, which often result in treatment failure. …”

Image 3_Vitexicarpin suppresses colorectal and non-small cell lung cancer via selective inhibition of Anoctamin 1.jpeg by Yohan Seo (773204)

“…<p>Colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) remain among the most challenging malignancies to treat due to therapy complexity, adverse events, and dose-limiting toxicities, which often result in treatment failure. …”

Image 2_Vitexicarpin suppresses colorectal and non-small cell lung cancer via selective inhibition of Anoctamin 1.jpeg by Yohan Seo (773204)

“…<p>Colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) remain among the most challenging malignancies to treat due to therapy complexity, adverse events, and dose-limiting toxicities, which often result in treatment failure. …”

Image 5_Vitexicarpin suppresses colorectal and non-small cell lung cancer via selective inhibition of Anoctamin 1.jpeg by Yohan Seo (773204)

“…<p>Colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) remain among the most challenging malignancies to treat due to therapy complexity, adverse events, and dose-limiting toxicities, which often result in treatment failure. …”

Image 1_Vitexicarpin suppresses colorectal and non-small cell lung cancer via selective inhibition of Anoctamin 1.jpeg by Yohan Seo (773204)

“…<p>Colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) remain among the most challenging malignancies to treat due to therapy complexity, adverse events, and dose-limiting toxicities, which often result in treatment failure. …”

Anticancer activity of thymoquinone in non-small cell lung cancer and possible involvement of PPAR-<i>γ</i> pathway by Mehmet Gurbilek (20720828)

“…The objective of this study was to assess the anticancer effects of TQ in non-small cell lung cancer (NSCLC) cells, and its effect on the peroxisome proliferator-activated receptor gamma (PPAR-<i>γ</i>) pathway.…”

Data Sheet 1_Lung microbiome alterations correlate with immune imbalance in non-small cell lung cancer.docx by Jiuling Cheng (16890546)

“…Background<p>Current understanding of the link between microbiota imbalance and immune function in non-small cell lung cancer (NSCLC) has not been fully elucidated. …”